We provide you with 20 years of free, institutional-grade data for RNAZ stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RNAZ. Explore the full financial landscape of RNAZ stock.
| Reported Date | CIK | Ticker | Type |
|---|
TransCode Therapeutics Inc(NASDAQ:RNAZ) 
TransCode Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for treating metastatic disease. The Company's development pipeline includes TTX-MC138, TTX-siPD-L1 and TTX-RIGA, TTX-siLIN28B, and TCD-miR10b.
Founded: 2016
CEO / Co-Founder: Michael Dudley
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Share this website to your friends
The information provided in this report about RNAZ stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.